Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals.

Jameel AbdulrehmanSahar ZarabiCarolyne Elbaz Kerstin de Wit Yulia Lin Michelle Sholzberg Rita Selby

Published in: Research and practice in thrombosis and haemostasis (2021)

Compared with clinical trial data, we found a numerically higher rate of mortality and similar rate of ATE and VTE among patients treated with idarucizumab in the real world.

Keyphrases

tertiary care
clinical trial
venous thromboembolism
healthcare
atrial fibrillation
cardiovascular events
electronic health record
risk factors
big data
randomized controlled trial
phase ii
study protocol
type diabetes
coronary artery disease
cardiovascular disease
machine learning